Electrochemical determination of fructosamine

• US 5,639,672 A
• Filed: 10/16/1995
• Issued: 06/17/1997
• Est. Priority Date: 10/16/1995
• Status: Expired due to Term

• Current Assignee: LXN Corporation (Johnson & Johnson)
• Original Assignee: LXN Corporation (Johnson & Johnson)
• Inventors: Burd, John F., Neyer, Gebhard
• Primary Examiner(s): Housel, James C.
• Assistant Examiner(s): Freed, Rachel
• Application Number:
  US08/543,482
• Time in Patent Office: 610 Days
• Field of Search: 436/525, 436/547, 436/63, 436/111, 436/151, 436/174, 436/806, 436/815, 422/82.01-82.03, 435/7.1
• US Class Current: 436/525
• CPC Class Codes: C12Q 1/005 involving specific analytes or enzymes including groups of enzymes, e.g. oxydases; C12Q1/004 takes precedence
• CPC Class Codes: G01N 33/553 Metal or metal coated
• CPC Class Codes: Y10S 436/806 Electrical property or magnetic property
• CPC Class Codes: Y10S 436/815 Test for named compound or class of compounds
• CPC Class Codes: Y10T 436/173845 Amine and quaternary ammonium
• CPC Class Codes: Y10T 436/25 including sample preparation

Abstract

The present invention relates to a method for electrochemically measuring the concentration of fructosamine, or its high alkalinity eneaminol tautomer in a body fluid sample.

Claims

1. A method for electrochemically determining the concentration of a fructosamine in a body fluid sample of a patient comprising the steps of:

a. contacting said body fluid sample with a buffering agent and a biosensor, said biosensor comprising an anode and a cathode;

b. applying a voltage to the anode;

c. measuring the electrical current passing between the anode and cathode; and

d. comparing the amount of current measured to a standard curve of current versus concentration of fructosamine, as determined for said body fluid in order to determine the concentration of the fructosamine in said body fluid;

wherein said buffering agent adjusts the pH of body fluid sample to between about 10 to about 12.5, and said buffering agent may be on the biosensor or otherwise added to the sample before the current is measured.

2. A method of claim 1, wherein the anode comprises a transition metal or a form of carbon.

3. A method of claim 2, wherein the anode is glassy carbon, platinum, or gold.

4. A method of claim 1, wherein the pH of the anolyte is adjusted to a pH of about 10.5 to about 11.5.

5. A method of claim 1, further comprising contacting a reference electrode simultaneously with the body fluid sample and measuring the voltage between the reference electrode and the anode.

6. A method of claim 5, wherein the reference electrode is a silver/silver chloride electrode.

7. A method of claim 1, additionally comprising:

a. contacting the body fluid sample with a second biosensor, said second biosensor utilizing the same buffering agent, anode and cathode as said biosensor;

b. contacting said body fluid sample with a fructosamine binding agent;

c. applying the identical voltage to the second anode;

d. additionally measuring the current between the anode and cathode of the second biosensor;

e. subtracting the current measured by the second biosensor from that measured for the other biosensor; and

f. comparing the difference of the two values to said standard curve;

wherein said fructosamine binding agent may be on the biosensor or otherwise added to said sample before the current is measured.

8. A method of claim 7, wherein the fructosamine binding agent is boric acid, one or more boronic acid derivatives, or one or more anti-(fructosamine) antibodies.

9. A method for electrochemically determining the concentration of a fructosamine in a body fluid sample of a patient, comprising the steps of:

a. contacting the body fluid sample with one or more mediators, a buffering agent and a biosensor comprised of an anode and cathode;

b. applying a voltage to the anode;

c. measuring the electrical current passing between the anode and cathode; and

d. comparing the amount of current measured to a standard curve of current versus concentration of fructosamine in the presence of said one or more mediators, as determined for said body fluid;

wherein said buffering agent and mediator are on the biosensor or otherwise added to the sample before said current is measured; and

said buffering agent adjusts the pH of said body fluid sample to between about 4 to about 12.5.

10. A method of claim 9, wherein the mediator is chosen from the group consisting of ferrocene, a nitro blue tetrazolium salt, a tris ruthenium complex, or a tris osmium complex.

11. A method of claim 10, wherein the anode comprises a transition metal or a form of carbon.

12. A method of claim 11, wherein the anode is glassy carbon, platinum, or gold.

13. A method of claim 9, wherein the pH of the body fluid sample is adjusted to a pH of about 10.5 to about 11.5.

14. A method of claim 9, additionally comprising contacting the body fluid sample with a reference electrode and measuring the voltage between the reference electrode and the anode.

15. A method of claim 14, wherein the reference electrode is a silver/silver chloride electrode.

16. A method of claim 10, wherein the mediator is a nitro blue tetrazolium salt and the pH is about 10.3.

17. A method of claim 10, wherein the mediator is ferrocene.

18. A method of claim 9, additionally comprising:

a. contacting the body fluid sample with a second biosensor, said second biosensor utilizing the same buffering agent, anode and cathode as said biosensor;

b. contacting said body fluid sample with a fructosamine binding agent;

c. applying the identical voltage to the second anode;

d. additionally measuring the current between the anode and cathode of the second biosensor;

e. subtracting the current measured by the second biosensor from that measured for the other biosensor; and

f. comparing the difference of the two values to said standard curve;

wherein said fructosamine binding agent may be on the biosensor or otherwise added to said sample before the current is measured.

19. A method of claim 18, wherein the fructosamine binding agent is boric acid, one or more boronic acid derivatives, or one or more anti-(fructosamine) antibodies.

20. A method for electrochemically determining the concentration of a fructosamine in a body fluid sample of a patient, comprising the steps of:

a. contacting the body fluid sample with an oxidoreductase enzyme, a buffering agent and a biosensor comprised of an anode and cathode;

b. applying a voltage to the anode;

c. measuring the electrical current passing between the anode and cathode; and

d. comparing the amount of current measured to a standard curve of current versus concentration of fructosamine in the presence of said oxidoreductase enzyme, as determined for said body fluid;

wherein said buffering agent and enzyme are on the biosensor or otherwise added to the sample before said current is measured; and

said buffering agent adjusts the pH of said body fluid sample to between about 4 to about 10.

21. A method of claim 20, additionally comprising contacting said body fluid sample with one or more mediators or factors, wherein said mediators is initially on the biosensor or otherwise is added to said sample before said current is measured.

22. A method of claim 20 or 21, wherein said enzyme is fructosyl N-alkyl amino acid oxidase or fructosylamine oxidase.

23. A method of claim 21, wherein said one or mediators or cofactors is ferrocene, nitro blue tetrazolium, a tris ruthenium complex, or a tris osmium complex.

24. A method of claim 21, wherein said mediators or cofactors are nicotinamide adenine dinucleotide or flavin adenine dinucleotide.

25. A method of claim 20, wherein the anode comprises a transition metal or a form of carbon.

26. A method of claim 25, wherein the anode is glassy carbon, platinum or gold.

27. A method of claim 20, further comprising simultaneously contacting said body fluid sample with a reference electrode and measuring the voltage between the reference electrode and the anode.

28. A method of claim 27, wherein said reference electrode is a silver/silver chloride electrode.